Australian biotech Microba brings gut analysis to Europe with pathology leader SYNLAB
Microbiome Gut Analysis logo MEDIA RELEASE Brisbane-based gut analysis experts Microba, have partnered with Europe’s largest medical diagnostic services provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
The partnership will bring together the cutting-edge metagenomics sequencing
and bioinformatics of Microba with the expertise of SYNLAB’s laboratory
services team to deliver new gastrointestinal analysis services to their
network of practising doctors and clinics.
Microba was developed out of field-leading research from the University of
Queensland, launching Australia’s first detailed gut microbiome analysis in
June 2018.
The biotech has now assisted more than 10,000 Australians to assess their gut
health individually or with an Australian healthcare professional.
SYNLAB is the market leader in medical diagnostic services in Europe, with a
presence in more than 40 countries across four continents.
The co-delivered MyBiome gut microbiome analysis will be launched initially
in two selected countries to provide healthcare professionals with access to
new and actionable information on their patients’ health.
Blake Wills, CEO of Microba, emphasised that the launch would expand the
availability of the company’s world-leading gut microbiome analysis
technology to customers in Europe, and assist Microba in their global
pursuit of driving new discoveries and improving human health.
“Microba’s partnership with SYNLAB is a great example of two international
forces joining together to embrace next-generation technologies and support
local healthcare,” said Wills.
“It will allow us to expand the reach of our technology into the European
market, and bring innovation born in Australia into larger overseas markets
to positively impact more lives,” he added.
Microba’s award-winning proprietary
Metagenomic Analysis Platform (MAP™) will be utilised to deliver the MyBiome
analysis.
Mr Wills said that delivering an analysis into the European market in
partnership with SYNLAB allowed Microba to access large, established markets
with unmet demand for comprehensive microbiome analysis services.
“SYNLAB is a global leader in delivering medical diagnostic services and we
are proud to be partnering to add advanced gut microbiome analysis to their
portfolio, powered by Microba’s technology,” he said.
Chief Medical Officer of SYNLAB Group, Dr Santiago Valor said, “We are
excited to start this collaboration with Microba. SYNLAB’s commitment to
medical excellence in diagnostics is underlined by complementing our test
portfolio with the MyBiome analysis.”
“Together we set a sign for continuous medical advancement to the benefit of
patients and customers.”
In addition to powering the new analysis service in Europe with SYNLAB, and a
continuing partnership in the United States, Microba also works with research
groups and healthcare organisations to advance global understanding of the
human gut microbiome and its influence on health.
ENDS
|